🏛️ Verified NIH Record • Updated 2026-07-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. (NCT05109728)
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
A Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Who can join: Review the eligibility criteria below.
Location: Col Uni Med Center New York Presby — New York, New York
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Col Uni Med Center New York Presby — New York, New York
- University of Pittsburgh — Pittsburgh, Pennsylvania
- MD Anderson Cancer Center Uni of Te — Houston, Texas
- University of Wisconsin School of Medicine and Public Health — Madison, Wisconsin
- Novartis Investigative Site — Bron,
- Novartis Investigative Site — Marseille,
- Novartis Investigative Site — Porto,
- Novartis Investigative Site — Granada, Andalusia
- Novartis Investigative Site — Barcelona,
- Novartis Investigative Site — Barcelona,
- Novartis Investigative Site — Madrid,
- Novartis Investigative Site — Madrid,
- Novartis Investigative Site — Lausanne,
- Novartis Investigative Site — Zurich,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glioblastoma
- Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma — Milwaukee, Wisconsin
- A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors — San Francisco, California
- Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma — Phoenix, Arizona
- A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma — Birmingham, Alabama
- Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma — Fairbanks, Alaska
Explore by condition: All Glioblastoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.